Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac troponin I after mRNA-1273.712 in adolescents and young adults
2025-000442-25Phase 4
- Sponsor
- Moderna Inc
- Start
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of mRNA-1273.712 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Moderna Inc. Primary endpoint: Number of Participants with Elevated cTnI Level at Day 4 or Day 32 (3 days After Injection 1 or Injection 2).
02
Drugs
mRNA-1273.712
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2025-000442-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000442-25.